Pulmatrix Drug Candidate Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA Biotech Investing
Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease Biotech Investing
Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication Biotech Investing
